Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66047, USA; Biopharmaceutical Innovation & Optimization Center, The University of Kansas, Lawrence, KS 66047, USA.
Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66047, USA.
Int J Pharm. 2024 Apr 10;654:123940. doi: 10.1016/j.ijpharm.2024.123940. Epub 2024 Feb 24.
This study aims to develop a new method to dry proteins based on protein-hyaluronic acid (HA) precipitation and apply the precipitation-redissolution technique to develop highly concentrated protein formulations. Lysozyme was used as a model protein and HA with various molecular weights (MW) were investigated. Under low ionic strength, low-MW HA (e.g., MW: around 5 K) did not induce lysozyme precipitation. Conversely, high-MW HA (e.g., MW: approximately from 40 K to 1.5 M) precipitated more than 90 % of lysozyme. The dried lysozyme-HA precipitates had moisture levels between 4 % and 5 %. The lysozyme-HA precipitates could be redissolved using PBS (pH 7.4, ionic strength: ∼ 163 mM). The viscosity of the reconstituted solution was dependent on HA MW, e.g., 4 cP for HA40K, and 155 cP for HA1.5 M, suggesting low-MW HA might be a proper excipient for highly concentrated solution formulations for subcutaneous/intraocular injection and high-MW HA may fit for other applications. The tertiary structure of lysozyme after the precipitation-redissolution steps had no significant difference from that of the original lysozyme as confirmed by fluorescence spectroscopy. The denaturation temperature of lysozyme after the precipitation-redissolution steps and that of the original lysozyme were close, indicating they possessed similar thermal stability. The accelerated stability study revealed that lysozyme stored in the dry precipitates was more physically stable than that in the buffer solution. Overall, this new drying technique is suitable for drying proteins and exhibits several benefits such as minimum energy consumption, cost effectiveness, high production yield, and mild processing conditions. In addition, the precipitation-redissolution technique proposed in this study can potentially be used to develop highly concentrated formulations, especially for proteins experiencing poor stability in the liquid state.
本研究旨在开发一种基于蛋白质-透明质酸(HA)沉淀的新型蛋白质干燥方法,并应用沉淀-再溶解技术开发高浓度蛋白质制剂。溶菌酶被用作模型蛋白,研究了不同分子量(MW)的 HA。在低离子强度下,低 MW HA(例如,MW:约 5 K)不会诱导溶菌酶沉淀。相反,高 MW HA(例如,MW:约 40 K 至 1.5 M)沉淀超过 90%的溶菌酶。干燥的溶菌酶-HA 沉淀物的水分含量在 4%至 5%之间。溶菌酶-HA 沉淀物可以使用 PBS(pH 7.4,离子强度:约 163 mM)重新溶解。重新配制溶液的粘度取决于 HA MW,例如,HA40K 为 4 cP,HA1.5 M 为 155 cP,表明低 MW HA 可能是适合皮下/眼内注射的高浓度溶液制剂的赋形剂,而高 MW HA 可能适用于其他应用。通过荧光光谱证实,沉淀-再溶解步骤后溶菌酶的三级结构与原始溶菌酶没有明显差异。沉淀-再溶解步骤后溶菌酶的变性温度与原始溶菌酶接近,表明它们具有相似的热稳定性。加速稳定性研究表明,储存在干燥沉淀物中的溶菌酶比储存在缓冲液中的溶菌酶更稳定。总的来说,这种新的干燥技术适用于干燥蛋白质,具有能耗低、成本效益高、生产产量高和处理条件温和等优点。此外,本研究提出的沉淀-再溶解技术可能用于开发高浓度制剂,特别是对于在液态下稳定性差的蛋白质。